View in EDS

Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.

Saved in:
Bibliographic Details
Title: Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.
Authors: Metrano AJ; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Morrill LA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Bommakanti G; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Casella R; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Cook S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Escobar RA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Giblin KA; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK., Gosselin E; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Grebe T; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Hariparsad N; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Howells R; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK., Lamont GM; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK., Mele DA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Pflug A; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Proia TA; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Rezaei H; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Richter M; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Richards R; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., San Martin M; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Schimpl M; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Schuller AG; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Sha L; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Sheppeck JE 2nd; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Song K; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Tang H; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK., Wagner DJ; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Wang J; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Wu A; Discovery Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA., Wu Y; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Xu K; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Ye M; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Shields JD; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com., Grimster NP; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.
Source: RSC medicinal chemistry [RSC Med Chem] 2025 May 27; Vol. 16 (8), pp. 3522-3529. Date of Electronic Publication: 2025 May 27 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101759460 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8682 (Electronic) Linking ISSN: 26328682 NLM ISO Abbreviation: RSC Med Chem Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40521343
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Metrano+AJ%22">Metrano AJ</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Morrill+LA%22">Morrill LA</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Bommakanti+G%22">Bommakanti G</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Casella+R%22">Casella R</searchLink>; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA.<br /><searchLink fieldCode="AU" term="%22Cook+S%22">Cook S</searchLink>; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA.<br /><searchLink fieldCode="AU" term="%22Escobar+RA%22">Escobar RA</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Giblin+KA%22">Giblin KA</searchLink>; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Gosselin+E%22">Gosselin E</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Grebe+T%22">Grebe T</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Hariparsad+N%22">Hariparsad N</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Howells+R%22">Howells R</searchLink>; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Lamont+GM%22">Lamont GM</searchLink>; Oncology R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Mele+DA%22">Mele DA</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Pflug+A%22">Pflug A</searchLink>; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Proia+TA%22">Proia TA</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Rezaei+H%22">Rezaei H</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Richter+M%22">Richter M</searchLink>; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Richards+R%22">Richards R</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22San+Martin+M%22">San Martin M</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Schimpl+M%22">Schimpl M</searchLink>; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Schuller+AG%22">Schuller AG</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Sha+L%22">Sha L</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Sheppeck+JE+2nd%22">Sheppeck JE 2nd</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Song+K%22">Song K</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Tang+H%22">Tang H</searchLink>; Discovery Sciences, R&D, AstraZeneca Cambridge CB2 0AA UK.<br /><searchLink fieldCode="AU" term="%22Wagner+DJ%22">Wagner DJ</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA.<br /><searchLink fieldCode="AU" term="%22Wu+A%22">Wu A</searchLink>; Discovery Sciences, R&D, AstraZeneca Waltham MA 02451 USA.<br /><searchLink fieldCode="AU" term="%22Wu+D%22">Wu D</searchLink>; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca Waltham MA 02451 USA.<br /><searchLink fieldCode="AU" term="%22Wu+Y%22">Wu Y</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Xu+K%22">Xu K</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Ye+M%22">Ye M</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Shields+JD%22">Shields JD</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Grimster+NP%22">Grimster NP</searchLink>; Oncology R&D, AstraZeneca Waltham MA 02451 USA anthony.metrano@astrazeneca.com lucas.morrill@astrazeneca.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101759460%22">RSC medicinal chemistry</searchLink> [RSC Med Chem] 2025 May 27; Vol. 16 (8), pp. 3522-3529. <i>Date of Electronic Publication: </i>2025 May 27 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Royal+Society+of+Chemistry%22">Royal Society of Chemistry </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101759460 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-8682 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226328682%22">26328682 </searchLink><i>NLM ISO Abbreviation: </i>RSC Med Chem <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40521343
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1039/d5md00309a
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3522
    Titles:
      – TitleFull: Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Metrano AJ
      – PersonEntity:
          Name:
            NameFull: Morrill LA
      – PersonEntity:
          Name:
            NameFull: Bommakanti G
      – PersonEntity:
          Name:
            NameFull: Casella R
      – PersonEntity:
          Name:
            NameFull: Cook S
      – PersonEntity:
          Name:
            NameFull: Escobar RA
      – PersonEntity:
          Name:
            NameFull: Giblin KA
      – PersonEntity:
          Name:
            NameFull: Gosselin E
      – PersonEntity:
          Name:
            NameFull: Grebe T
      – PersonEntity:
          Name:
            NameFull: Hariparsad N
      – PersonEntity:
          Name:
            NameFull: Howells R
      – PersonEntity:
          Name:
            NameFull: Lamont GM
      – PersonEntity:
          Name:
            NameFull: Mele DA
      – PersonEntity:
          Name:
            NameFull: Pflug A
      – PersonEntity:
          Name:
            NameFull: Proia TA
      – PersonEntity:
          Name:
            NameFull: Rezaei H
      – PersonEntity:
          Name:
            NameFull: Richter M
      – PersonEntity:
          Name:
            NameFull: Richards R
      – PersonEntity:
          Name:
            NameFull: San Martin M
      – PersonEntity:
          Name:
            NameFull: Schimpl M
      – PersonEntity:
          Name:
            NameFull: Schuller AG
      – PersonEntity:
          Name:
            NameFull: Sha L
      – PersonEntity:
          Name:
            NameFull: Sheppeck JE 2nd
      – PersonEntity:
          Name:
            NameFull: Song K
      – PersonEntity:
          Name:
            NameFull: Tang H
      – PersonEntity:
          Name:
            NameFull: Wagner DJ
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Wu A
      – PersonEntity:
          Name:
            NameFull: Wu D
      – PersonEntity:
          Name:
            NameFull: Wu Y
      – PersonEntity:
          Name:
            NameFull: Xu K
      – PersonEntity:
          Name:
            NameFull: Ye M
      – PersonEntity:
          Name:
            NameFull: Shields JD
      – PersonEntity:
          Name:
            NameFull: Grimster NP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 05
              Text: 2025 May 27
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2632-8682
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: RSC medicinal chemistry
              Type: main
ResultId 1